Early development evaluation of AZD2738, a substrate for the NK receptors

Drug Development and Industrial Pharmacy

Volumn 37, Issue 6, 2011, Pages 719-726

  Sigfridsson, Kalle ^a,b   Ahlqvist, Matti ^a   Lindsjö, Martin ^a   Paulsson, Stefan ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

NK receptor; preformulation; salt screen; solid state; stability

Indexed keywords

AZD 2738; FUMARIC ACID; MALEIC ACID; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR ANTAGONIST; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; NONHUMAN; PHYSICAL CHEMISTRY; SOLID STATE; THERMOGRAVIMETRY; WETTABILITY; X RAY POWDER DIFFRACTION;

AZETIDINES; BENZAMIDES; CRYSTALLIZATION; DRUG STABILITY; FREEZING; HYDROGEN-ION CONCENTRATION; RECEPTORS, NEUROKININ-1; RECEPTORS, NEUROKININ-2; SALTS; SOLUBILITY; WETTABILITY;

EID: 79955964590     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.538060     Document Type: Article

References (31)

1. Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA. (2004). Tachykinins and tachykinin receptors: a growing family. Life Sci, 74:1445-1463. (Pubitemid 38077208)
2. Quartara L, Altamura M. (2006). Tachykinin receptors antagonists: from research to clinic. Curr Drug Targets, 7:975-992. (Pubitemid 44227581)
3. Holzer P, Holzer-Petsche U. (2001). Tachykinin receptors in the gut: physiological and pathological implications. Curr Opin Pharmacol, 1:583-590. (Pubitemid 33585999)
4. Naline E, Devillier P, Drapeau G, Toty L, Bakdach H, Regoli D et al. (1989). Characterization of neurokinin effects and receptor selectivity in human isolated bronchi. Am Rev Respir Dis, 140:679-686. (Pubitemid 19234313)
5. Tsuchida K, Shigemoto R, Yokota Y, Nakanishi S. (1990). Tissue distribution and quantitation of the mRNAs for three rat tachykinin receptors. Eur J Biochem, 193:751-757. (Pubitemid 20381706)
6. Pennefather JN, Zeng XP, Gould D, Hall S, Burcher E. (1993). Mammalian tachykinins stimulate rat uterus by activating NK-2 receptors. Peptides, 14:169-174.
7. Croci T, Aureggi G, Manara L, Emonds-Alt X, Le Fur G, Maffrand JP et al. (1998). In vitro characterization of tachykinin NK2-receptors modulating motor responses of human colonic muscle strips. Br J Pharmacol, 124:1321-1327. (Pubitemid 28333959)
8. Saffroy M, Torrens Y, Glowinski J, Beaujouan JC. (2001). Presence of NK2 binding sites in the rat brain. J Neurochem, 79: 985-996. (Pubitemid 33117077)
9. Saffroy M, Torrens Y, Glowinski J, Beaujouan JC. (2003). Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites. Neuroscience, 116:761-773. (Pubitemid 36160572)
10. Massi M, Panocka I, de Caro G. (2000). The psychopharmacology of tachykinin NK-3 receptors in laboratory animals. Peptides, 21:1597-1609.
11. Page NM, Bell NJ. (2002). The human tachykinin NK1 (short form) and tachykinin NK4 receptor: a reappraisal. Eur J Pharmacol, 437:27-30.
12. Patak E, Candenas ML, Pennefather JN, Ziccone S, Lilley A, Martín JD et al. (2003). Tachykinins and tachykinin receptors in human uterus. Br J Pharmacol, 139:523-532. (Pubitemid 36819622)
13. Fioramonti J, Gaultier E, Toulouse M, Sanger GJ, Bueno L. (2003). Intestinal anti-nociceptive behaviour of NK3 receptor antagonism in conscious rats: evidence to support a peripheral mechanism of action. Neurogastroenterol Motil, 15:363-369. (Pubitemid 36876251)
14. Lecci A, Maggi CA. (2003). Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases. Expert Opin Ther Targets, 7:343-362. (Pubitemid 36722220)
15. Jankovic B, Mentus S. (2010). Thermal stability and nonisothermal kinetics of Folnak degradation process. Drug Dev Ind Pharm, 36:980-992.
16. Haleblian J, McCrone W. (1969). Pharmaceutical applications of polymorphism. J Pharm Sci, 58:911-929.
17. Threlfall TL. (1995). Analysis of organic polymorphs. A review. Analyst, 120:2435-2460.
18. Grant DJW, Higuchi T. (1990). Solubility behavior of organic compounds. New York: Wiley, 600.
19. Grant DJW, Brittain HG. (1995). Solubility of pharmaceutical solids. In: Brittain HG, ed. Physical characterization of pharmaceutical solids. New York: Marcel Dekker, 321-386.
20. Brittain HG, Grant DJW. (1999). Effects o f polymorphism and solid-state salvation on solubility and dissolution rate. In: Brittain HG, ed. Polymorphism in pharmaceutical solids. New York: Marcel Dekker, 279-330.
21. Yu L, Stephenson GA, Mitchell CA, Bunnell CA, Snorek SV, Bowyer JJ, et al. (2000). Thermochemistry and conformational polymorphism of a hexamorphic crystal system. J Am Chem Soc, 122:585-591. (Pubitemid 30090495)
22. Sun C, Grant DJ. (2001). Influence of crystal structure on the tableting properties of sulfamerazine polymorphs. Pharm Res, 18:274-280. (Pubitemid 32595813)
23. Sun C, Grant DJ. (2004). Improved tableting properties of p-hydroxybenzoic acid by water of crystallization: a molecular insight. Pharm Res, 21:382-386. (Pubitemid 38221986)
24. Chen X, Morris KR, Griesser UJ, Byrn SR, Stowell JG. (2002). Reactivity differences of indomethacin solid forms with ammonia gas. J Am Chem Soc, 124:15012-15019. (Pubitemid 36014109)
25. Bernstein J. (2002). Polymorphism in molecular crystals. Oxford, UK: Oxford University Press, 297-307.
26. Berge SM, Bighley LD, Monkhouse DC. (1977). Pharmaceutical salts. J Pharm Sci, 66:1-19.
27. Gould PL. (1986). Salt selection for basic drugs. Int J Pharm, 33:201-217. (Pubitemid 17197805)
28. Stahl PH, Wermuth CG, eds. (2002). Handbook of pharmaceutical salts, properties, selection and use. Weinheim: IUPAC, Wiley-VCH.
29. Lennernäs H, Abrahamsson B. (2005). The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol, 57:273-285. (Pubitemid 40326200)
30. Gupta E, Barends DM, Yamashita E, Lentz KA, Harmsze AM, Shah VP et al. (2006). Review of global regulations concerning biowaivers for immediate release solid oral dosage forms. Eur J Pharm Sci, 29:315-324. (Pubitemid 44602408)
31. Kortejärvi H, Urtti A, Yliperttula M. (2007). Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates. Eur J Pharm Sci, 30:155-166. (Pubitemid 46157177)